Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Current Deferred Revenue: 2010-2024

Historic Current Deferred Revenue for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Dec 2024 value amounting to $7.4 million.

  • Lineage Cell Therapeutics' Current Deferred Revenue fell 54.35% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 million, marking a year-over-year decrease of 54.35%. This contributed to the annual value of $7.4 million for FY2024, which is 31.64% down from last year.
  • According to the latest figures from FY2024, Lineage Cell Therapeutics' Current Deferred Revenue is $7.4 million, which was down 31.64% from $10.8 million recorded in FY2023.
  • In the past 5 years, Lineage Cell Therapeutics' Current Deferred Revenue registered a high of $50.5 million during FY2021, and its lowest value of $193,000 during FY2020.
  • For the 3-year period, Lineage Cell Therapeutics' Current Deferred Revenue averaged around $9.2 million, with its median value being $9.4 million (2022).
  • Per our database at Business Quant, Lineage Cell Therapeutics' Current Deferred Revenue surged by 26,065.80% in 2021 and then tumbled by 81.34% in 2022.
  • Yearly analysis of 5 years shows Lineage Cell Therapeutics' Current Deferred Revenue stood at $193,000 in 2020, then spiked by 26,065.80% to $50.5 million in 2021, then crashed by 81.34% to $9.4 million in 2022, then increased by 14.72% to $10.8 million in 2023, then plummeted by 31.64% to $7.4 million in 2024.